Suzanne Roy

Suzanne Roy serves as Black Diamond’s VP, Program Team Lead overseeing Black Diamond’s two lead programs. Suzanne brings over 20 years of experience leading small molecule, biologic and immunotherapy Project Teams driving the product strategy and execution from pre-IND through commercialization.

Prior to Black Diamond, Suzanne was Vice President, Program Team Leadership at Chinook Therapeutics leading an immunotherapy program in clinical development and was a key member of the Aduro/Chinook Transition team during the merger. Previously as VP, Development Programs & Project Leadership at Aduro Biotech, she led a variety of monoclonal antibody and immunotherapy programs in clinical development as well as leading the Project Team Leader and Project Management groups. In these positions Suzanne drove the development of cross-functional Product Strategy planning and execution. Prior to Aduro Suzanne led a targeted small molecule program at Clovis Oncology from molecule selection to NDA/EMA submission, along with a PMA submission for a companion diagnostic. Earlier in her career, Suzanne began as a scientist at Amgen, developing clinical and commercial formulations for proteins and antibodies, but transitioned full time into Project Team Leadership driving program strategy and execution for a variety of programs in preclinical, clinical, and commercial stages of development. She holds a BS in Biochemistry and Molecular Biology from UCSB, a Ph.D. in Pharmaceutical Chemistry from the University of Kansas and an MBA from UCLA.